Drug Profile

TGTX 109

Alternative Names: TGTX-109; TSHA-109

Latest Information Update: 28 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Texas Southwestern Medical Center
Developer Taysha Gene Therapies; University of Texas Southwestern Medical Center
Class Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 May 2024 No recent reports of development identified for preclinical development in Inborn-error-metabolic-disorders in USA (Intrathecal)
29 Apr 2020 Taysha Gene Therapies in-licenses TGTX 109 from University of Texas Southwestern Medical Center
29 Apr 2020 Preclinical trials in Inborn error metabolic disorders in USA (Intrathecal) before April 2020 (Taysha Gene Therapies pipeline, April 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com